Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.

International journal of clinical pharmacology and therapeutics

Volumn 42, Issue 11, 2004, Pages 642-643

  Ritter, C A ^a   Bianco, R ^a   Dugger, T ^a   Forbes, J ^a   Qu, S ^a   Rinehart, C ^a   King, W ^a   Arteaga, C L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; MOUSE; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; MICE; MICE, INBRED BALB C; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RECEPTOR, ERBB-2;

EID: 16644385065     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42642     Document Type: Article

References (0)